Capecitabine and the Risk of Fingerprint Loss

JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638.

Authors

Leni van Doorn¹, Sebastiaan Veelenturf², Lisette Binkhorst³, Sander Bins¹, Ron Mathijssen¹

Affiliations

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
² Regional Criminal Investigations Division, National Police, The Hague, the Netherlands.
³ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands3Apotheek Haagse Ziekenhuizen/HagaZiekenhuis, The Hague, the Netherlands.

PMID: 27560202
DOI: 10.1001/jamaoncol.2016.2638

No abstract available

MeSH terms

Capecitabine / adverse effects*
Capecitabine / therapeutic use
Carcinoma, Hepatocellular / complications
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / pathology
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology
Dermatoglyphics
Female
Fluorouracil / adverse effects
Hand-Foot Syndrome / etiology
Hand-Foot Syndrome / pathology
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Male
Skin Diseases, Genetic / chemically induced
Skin Diseases, Genetic / pathology*

Substances

Capecitabine
Fluorouracil

Supplementary concepts

Fingerprints, Absence of